Pharmaceuticals, Biotechnology and Life Sciences
Vifor Pharma has announced full results from its phase-IIIb DIAMOND trial showing that Veltassa allowed patients to achieve long-term potassium control, reduced the risk of recurrent hyperkalemia and prolonged optimized and guideline recommended renin-angiotensin aldosterone system inhibitor (RAASi) therapy.
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of CSL Limited (ASX: CSL; USOTC: CSLLY), have announced the definitive notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348) for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.
CSL Behring AG, a wholly-owned subsidiary of global biotechnology leader CSL Limited has announced the definitive notice of the Interim Result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.
ST GALLEN, Switzerland–(BUSINESS WIRE)–Regulatory News: Vifor Pharma today announced changes to its management. Dr Klaus Henning Jensen will join the…
Standard & Poor’s (S&P) assigned a BBB- credit rating with stable outlook to Vifor Pharma.
Strong financial performance in H1 2019 Continued positive performance of all three strategic growth drivers Guidance raised on 2019 net…
phase-II AMBER study whichdemonstrated that a significantly higher proportion of patients withresistant hypertension (RHTN) and chronic kidney disease (CKD) takingVeltassa® (patiromer) remained on spironolactone therapycompared to patients taking placebo at week 12.
Vifor Pharma Group has granted Japanese company Zeria Pharmaceutical exclusive rights to develop and commercialise Veltassa, its sodium-free potassium binder approved…
Vifor Pharma has posted strong net sales in the first half of 2017, driven by its three medium-term strategic growth drivers. It had net net profit after minorities of CHF1,094 M, ($1,124M)in the first half, compared to the same period last year of CHF158.9.